title: Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma.
abstract: Antibodies against CD47, which block tumor cell CD47 interactions with macrophage signal regulatory protein-α, have been shown to decrease tumor size in hematological and epithelial tumor models by interfering with the protection from phagocytosis by macrophages that intact CD47 bestows upon tumor cells. Leiomyosarcoma (LMS) is a tumor of smooth muscle that can express varying levels of colony-stimulating factor-1 (CSF1), the expression of which correlates with the numbers of tumor-associated macrophages (TAMs) that are found in these tumors. We have previously shown that the presence of TAMs in LMS is associated with poor clinical outcome and the overall effect of TAMs in LMS therefore appears to be protumorigenic. However, the use of inhibitory antibodies against CD47 offers an opportunity to turn TAMs against LMS cells by allowing the phagocytic behavior of resident macrophages to predominate. Here we show that interference with CD47 increases phagocytosis of two human LMS cell lines, LMS04 and LMS05, in vitro. In addition, treatment of mice bearing subcutaneous LMS04 and LMS05 tumors with a novel, humanized anti-CD47 antibody resulted in significant reductions in tumor size. Mice bearing LMS04 tumors develop large numbers of lymph node and lung metastases. In a unique model for neoadjuvant treatment, mice were treated with anti-CD47 antibody starting 1 wk before resection of established primary tumors and subsequently showed a striking decrease in the size and number of metastases. These data suggest that treatment with anti-CD47 antibodies not only reduces primary tumor size but can also be used to inhibit the development of, or to eliminate, metastatic disease.
authors.affiliation: Department of Pathology, Stanford University Medical Center, Stanford, CA 94305, USA.
authors.forename: Badreddin
authors.initials: B
authors.lastname: Edris
authors.forename: Kipp
authors.initials: K
authors.lastname: Weiskopf
authors.forename: Anne K
authors.initials: AK
authors.lastname: Volkmer
authors.forename: Jens-Peter
authors.initials: JP
authors.lastname: Volkmer
authors.forename: Stephen B
authors.initials: SB
authors.lastname: Willingham
authors.forename: Humberto
authors.initials: H
authors.lastname: Contreras-Trujillo
authors.forename: Jie
authors.initials: J
authors.lastname: Liu
authors.forename: Ravindra
authors.initials: R
authors.lastname: Majeti
authors.forename: Robert B
authors.initials: RB
authors.lastname: West
authors.forename: Jonathan A
authors.initials: JA
authors.lastname: Fletcher
authors.forename: Andrew H
authors.initials: AH
authors.lastname: Beck
authors.forename: Irving L
authors.initials: IL
authors.lastname: Weissman
authors.forename: Matt
authors.initials: M
authors.lastname: van de Rijn
mesh_terms: D000818:Animals; D000906:Antibodies / Q000276:immunology / Q000627:therapeutic use*; D051928:CD47 Antigen / Q000276:immunology*; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D007167:Immunotherapy; D007890:Leiomyosarcoma / Q000473:pathology / Q000628:therapy*; D051379:Mice; D009362:Neoplasm Metastasis; D010587:Phagocytosis / Q000276:immunology
chemical_list: D000906:Antibodies; D051928:CD47 Antigen